Abstract: Objective To evaluate the clinical value of detecting vascular endothelial growth factor(VEGF)in ascites and infusing cisplatin(DDP)in combination with thalidomide into abdominal cavity as maintenance therapy for advanced ovarian cancer.Methods 69 patients medical records of no combined chemotherapy tolerance and positive ascites VEGF in advanced ovarian cancer were analyzed retrospectively.36 were enrolled into the trial groupe(infusing cisplatin and thalidomide into abdominal cavity),and 33 were enrolled into the control groupe(the only abdominal cisplatin infusion).Therapies were take as follow:DDP(40~60/m²)was given once a week for 2 weeks,and repeated with an interval of 2weeks.every 28 day was a cycle.Thalidomide was given continuously.Efficacy and toxicity and immune function were evaluated after 2 cycles.Results Respone rate of the trial groupe was 72.2%,and respone rate of the control group was 46.9%,differences between the two groups was significant in statistics science(P＜0.05).VEGF level before treatment and after 2 cycles treatment were different in the two groups(P＜0.01).VEGF descent degree of the trial groupe was higher than that of the contronl.The percent of CD3⁺ 、CD4⁺ 、CD8⁺ and CD4⁺/CD8⁺ in front of treatment and behind of 2 cycles treatment were no differences in the two groups,differences was significant in statistics science(P＞0.05).The rate of Ⅲ-Ⅳgastroenteric toxicity in the trial groupe was less than that in the control groupe(P＜0.05).But,the rate of other Ⅲ-Ⅳ toxicity(for example:neutrocytopenia、hemoglobin descent、weakness)were no significant difference t in two groups(P＞0.05).Conclusion Detecting VEGF in ascites can increase diagnosis rate of malignant ascites.Infusing DDP into abdominal cavity in combination with thalidomide can raise respone rate in advanced ovarian cancer,reduce VEGF level of ascites,improve live quality and reduce adverse reaction.Patients tolerance and compliance are satisfactory.